<rss version="2.0" 
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
>

<channel>
	<title>News on Arbeitsgemeinschaft Osterreichischer Krankenhausapotheker from BioPortfolio.com</title>
	<link>http://www.BioPortfolio.com</link>
	<description>Consolidated Arbeitsgemeinschaft Osterreichischer Krankenhausapotheker news from BioPortfolio.com</description>
	<pubDate>Wed, 10 Feb 2010 04:36:19 GMT</pubDate>
	<language>en</language>
<atom:link href="http://www.bioportfolio.co.uk/cgi-bin/rssnews.pl?q=Arbeitsgemeinschaft+Osterreichischer+Krankenhausapotheker" rel="self" type="application/rss+xml" />

	
<item><title>Notes from the 37th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF), Berlin, www.adf</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3923000&amp;HITNO=0&amp;MSIZE=5&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Arbeitsgemeinschaft%20Osterreichischer%20Krankenhausapotheker&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3923000&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2476357463%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3923000&amp;HITNO=0&amp;MSIZE=5&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Arbeitsgemeinschaft%20Osterreichischer%20Krankenhausapotheker&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3923000&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2476357463%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Bioscience Technology Online:</description></item>
<item><title>Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3912171&amp;HITNO=1&amp;MSIZE=5&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Arbeitsgemeinschaft%20Osterreichischer%20Krankenhausapotheker&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3912171&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2470106015%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3912171&amp;HITNO=1&amp;MSIZE=5&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Arbeitsgemeinschaft%20Osterreichischer%20Krankenhausapotheker&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3912171&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2470106015%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>MDLinx:</description></item>
<item><title>Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3903114&amp;HITNO=2&amp;MSIZE=5&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Arbeitsgemeinschaft%20Osterreichischer%20Krankenhausapotheker&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3903114&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2465012671%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3903114&amp;HITNO=2&amp;MSIZE=5&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Arbeitsgemeinschaft%20Osterreichischer%20Krankenhausapotheker&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3903114&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2465012671%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>British Journal of Cancer:</description></item>
<item><title>AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3684998&amp;HITNO=3&amp;MSIZE=5&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Arbeitsgemeinschaft%20Osterreichischer%20Krankenhausapotheker&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3684998&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2355677147%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3684998&amp;HITNO=3&amp;MSIZE=5&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Arbeitsgemeinschaft%20Osterreichischer%20Krankenhausapotheker&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3684998&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2355677147%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Pharma Live:</description></item>
<item><title>AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3684136&amp;HITNO=4&amp;MSIZE=5&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Arbeitsgemeinschaft%20Osterreichischer%20Krankenhausapotheker&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3684136&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2355354050%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=3684136&amp;HITNO=4&amp;MSIZE=5&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Arbeitsgemeinschaft%20Osterreichischer%20Krankenhausapotheker&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=3684136&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2355354050%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>PR Newswire:</description></item>
</channel></rss>